Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Schram, A.; Goto, K.; Kim, D. W.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; Macarulla, T.; Liu, S. V.; Al-Hallak, M. N.; Cleary, J.; Neuzillet, C.; Goto, Y.; Joe, A. K.; Adeyemi, S.; Jauhari, S.; Drilon, A. |
| Abstract Title: | Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S756 |
| End Page: | S757 |
| Language: | English |
| ACCESSION: | WOS:001087480201639 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2023.09.2349 |
| Notes: | Meeting Abstract: 1315MO -- Source: Wos |
